Navigation Links
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Date:3/2/2010

king Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA and MAA filings. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail in the risk factors attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulator
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... executives hold high expectations that information technology will reduce ... however.  Earley & Associates, the nation,s foremost information management ... series titled Digitization of the Healthcare Industry ... on Wednesday, May 4 from 1-2 p.m. ...
... 3, 2011 Talecris Biotherapeutics Holdings Corp. (NASDAQ: ... Chapel Hill, N.C., where four proposals were submitted to, and ... the company,s Board of Directors to hold office for a ... and until their successors are elected and qualified. The three ...
... Inc. (Nasdaq: NVAX ) will report financial results ... 2011, before the U.S. financial markets open.  The announcement will ... Stanley C. Erck, President and Chief Executive Officer, and other ... The webcast and conference call will be available ...
Cached Biology Technology:Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 2Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 3Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting 2
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Pathogens , Francisella tularensis , the cause of ... is considered a potential biological weapon because it is readily ... in humans. While a live attenuated vaccine strain has ... to understand the basis for its attenuated virulence. In ...
... Universitt Mnchen (TUM) under Prof. Peter Schieberle and at the ... edible fats and oils: Lard, butterfat, rapeseed oil and olive ... ate 500 grams of low-fat yoghurt enriched with one of ... supplement to their normal diet. "Olive oil had the ...
... series across both genders continue to remain alarmingly low ... patient education and increased public vaccine financing programs are ... Texas Medical Branch (UTMB). The researchers report ... published in Cancer, Human Vaccines & Immunotherapeutics ...
Cached Biology News:News tips from the journal mBio®, volume 4, issue 1 2Olive oil makes you feel full 2HPV vaccine trends point to failures in patient education, vaccine programs 2
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Request Info...
... ideal for both radioactive and nonradioactive labeling ... Provides five pre-mixed nucleotide solutions for flexibility ... 8 cpm/g control DNA using [-32P]-dCTP ... performance of the system Labels 1 ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Biology Products: